Video Experimental Relacionado
Updated: Jul 17, 2026
10:33
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Un inhibidor de la desaminasa de adenosina no nucleósido altamente potente: descubrimiento de fármacos eficientes
Tadashi Terasaka1, Takayoshi Kinoshita, Masako Kuno
1Medicinal Chemistry Research Laboratories, Basic Research Laboratories, and Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., 2-1-6, Kashima, Yodogawa-ku, Osaka 532-8514, Japan.
Journal of the American Chemical Society
|January 8, 2004
Resumen
Los investigadores descubrieron rápidamente un potente inhibidor no nucleósido de la adenosina desaminasa (ADA) mediante la combinación de dos pistas moleculares distintas. Este enfoque de descubrimiento de fármacos acelera la identificación de nuevas entidades químicas para el desarrollo terapéutico.
Área de la Ciencia:
- La bioquímica es la bioquímica.
- Química Medicinal La Química Medicinal es un campo de estudio de la química medicinal.
- Descubrimiento de Drogas Descubrimiento de Drogas
Sus antecedentes:
- La adenosina desaminasa (ADA) es una enzima crítica en la función inmune.
- El desarrollo de potentes inhibidores de ADA es un objetivo clave en el descubrimiento de fármacos.
- Los inhibidores existentes pueden tener limitaciones en potencia o especificidad.
Objetivo del estudio:
- Descubrir rápidamente un inhibidor no nucleósido altamente potente de la adenosina desaminasa (ADA).
- Para utilizar una estrategia de hibridación de plomo informado por la biología estructural.
- Demostrar un enfoque eficiente para la identificación de nuevos fármacos candidatos.
Principales métodos:
- El diseño racional del fármaco y el cribado aleatorio se emplearon para identificar los inhibidores iniciales.
- Se determinaron las estructuras cristalinas de la ADA bovina con inhibidores para comprender la unión.
- El diseño de fármacos basado en la estructura se utilizó para la hibridación del plomo.
Principales resultados:
- Se descubrió el primer inhibidor de la ADA no nucleósido altamente potente con un Ki de 7,7 nM.
- Los inhibidores micromolares iniciales revelaron nuevos sitios y modos de unión.
- La hibridación del plomo en dos iteraciones produjo compuestos altamente efectivos.
Conclusiones:
- Se desarrolló una estrategia rápida y eficiente para descubrir potentes inhibidores de la ADA.
- La hibridación de plomo basada en la estructura acelera significativamente el descubrimiento de fármacos.
- Este enfoque es ampliamente aplicable para la identificación de nuevas entidades químicas.
Videos de Conceptos Relacionados
01:30Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:30Combined Effects of Drugs: Antagonism
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
01:27Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
01:26Enhanced Elimination of Poison
Poison can be effectively removed from the gastrointestinal (GI) tract through various decontamination procedures.
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...